http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 04 Sep 2026 18:02:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Conavi+Medical+Announces+Media+and+Digital+Marketing+Agreements/27030823.html <p>TORONTO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- <strong>Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), </strong>a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced that it has entered into media and digital marketing agreements to support increased market awareness of the Company.</p> <p><strong>Media and Digital Marketing Agreements</strong></p> <p>Conavi Medical has entered into a media services agreement with Market One Media Group (“Market One”). Market One, with offices in Vancouver and Toronto, is a multiplatform media solution for the capital markets operating in http://www.streetinsider.com/Press+Releases/Conavi+Medical+Announces+Media+and+Digital+Marketing+Agreements/27030823.html Fri, 04 Sep 2026 18:02:00 -0400 CNVI http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Announces+Media+and+Digital+Marketing+Agreements/27030823.html <p>TORONTO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- <strong>Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), </strong>a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced that it has entered into media and digital marketing agreements to support increased market awareness of the Company.</p> <p><strong>Media and Digital Marketing Agreements</strong></p> <p>Conavi Medical has entered into a media services agreement with Market One Media Group (“Market One”). Market One, with offices in Vancouver and Toronto, is a multiplatform media solution for the capital markets operating in http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Announces+Media+and+Digital+Marketing+Agreements/27030823.html Fri, 04 Sep 2026 18:02:00 -0400 CNVI http://www.streetinsider.com/SEC+Filings/Form++D++++++++++Conavi+Medical+Corp.+++++++++++++++++/27000877.html si-local-file:///var/storage/secattach/20260831/27000877.html http://www.streetinsider.com/SEC+Filings/Form++D++++++++++Conavi+Medical+Corp.+++++++++++++++++/27000877.html Mon, 31 Aug 2026 07:01:00 -0400 CNVI http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Press+Releases/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html <ul><li><em>Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) </em></li><li><em>Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering </em></li><li><em>Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone Payment</em></li><li><em>Achieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System</em></li><li><em>Added to Clinical Evidence Supporting Hybrid IVUS-OCT Imaging</em><br/></li></ul> <p>TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) --  Conavi Medical Corp. (TSXV: CNVI) http://www.streetinsider.com/Globe+Newswire/Conavi+Medical+Reports+Fiscal+Third+Quarter+2026+Results+and+Operational+Highlights/26985125.html Thu, 27 Aug 2026 08:03:00 -0400 A.06822034 A.29121491 A.50201113 CNVI CNVIF O.03299703 O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Press+Releases/Conavi+Medical+Announces+JSCAI+Publication+Demonstrating+the+Clinical+Utility+of+Hybrid+IVUS+OCT+Imaging/26744277.html <p>TORONTO, July 08, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced the publication of a case report in the <em>Journal of the Society for Cardiovascular Angiography &amp; Interventions</em> (“JSCAI”) titled “Versatility of Hybrid OCT and IVUS Imaging Enhances Contrast-Sparing Management of Eruptive Calcified Nodules.” The publication features Conavi’s hybrid intravascular ultrasound (“IVUS”) and optical coherence tomography (“OCT”) imaging system in a complex coronary procedure involving a patient with impaired renal function, http://www.streetinsider.com/Press+Releases/Conavi+Medical+Announces+JSCAI+Publication+Demonstrating+the+Clinical+Utility+of+Hybrid+IVUS+OCT+Imaging/26744277.html Wed, 08 Jul 2026 07:35:00 -0400 A.06822034 A.29121491 CNVI CNVIF O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Press+Releases/Conavi+Medical+Announces+JSCAI+Publication+Demonstrating+the+Clinical+Utility+of+Hybrid+IVUS+OCT+Imaging/26744277.html <p>TORONTO, July 08, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced the publication of a case report in the <em>Journal of the Society for Cardiovascular Angiography &amp; Interventions</em> (“JSCAI”) titled “Versatility of Hybrid OCT and IVUS Imaging Enhances Contrast-Sparing Management of Eruptive Calcified Nodules.” The publication features Conavi’s hybrid intravascular ultrasound (“IVUS”) and optical coherence tomography (“OCT”) imaging system in a complex coronary procedure involving a patient with impaired renal function, http://www.streetinsider.com/Press+Releases/Conavi+Medical+Announces+JSCAI+Publication+Demonstrating+the+Clinical+Utility+of+Hybrid+IVUS+OCT+Imaging/26744277.html Wed, 08 Jul 2026 07:35:00 -0400 A.06822034 A.29121491 CNVI CNVIF O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Press+Releases/Conavi+Medical+Announces+JSCAI+Publication+Demonstrating+the+Clinical+Utility+of+Hybrid+IVUS+OCT+Imaging/26744277.html <p>TORONTO, July 08, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced the publication of a case report in the <em>Journal of the Society for Cardiovascular Angiography &amp; Interventions</em> (“JSCAI”) titled “Versatility of Hybrid OCT and IVUS Imaging Enhances Contrast-Sparing Management of Eruptive Calcified Nodules.” The publication features Conavi’s hybrid intravascular ultrasound (“IVUS”) and optical coherence tomography (“OCT”) imaging system in a complex coronary procedure involving a patient with impaired renal function, http://www.streetinsider.com/Press+Releases/Conavi+Medical+Announces+JSCAI+Publication+Demonstrating+the+Clinical+Utility+of+Hybrid+IVUS+OCT+Imaging/26744277.html Wed, 08 Jul 2026 07:35:00 -0400 A.06822034 A.29121491 CNVI CNVIF O.07072321 O.20026344 O.29940178 http://www.streetinsider.com/Press+Releases/Conavi+Medical+Announces+JSCAI+Publication+Demonstrating+the+Clinical+Utility+of+Hybrid+IVUS+OCT+Imaging/26744277.html <p>TORONTO, July 08, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced the publication of a case report in the <em>Journal of the Society for Cardiovascular Angiography &amp; Interventions</em> (“JSCAI”) titled “Versatility of Hybrid OCT and IVUS Imaging Enhances Contrast-Sparing Management of Eruptive Calcified Nodules.” The publication features Conavi’s hybrid intravascular ultrasound (“IVUS”) and optical coherence tomography (“OCT”) imaging system in a complex coronary procedure involving a patient with impaired renal function, http://www.streetinsider.com/Press+Releases/Conavi+Medical+Announces+JSCAI+Publication+Demonstrating+the+Clinical+Utility+of+Hybrid+IVUS+OCT+Imaging/26744277.html Wed, 08 Jul 2026 07:35:00 -0400 A.06822034 A.29121491 CNVI CNVIF O.07072321 O.20026344 O.29940178